These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956 [TBL] [Abstract][Full Text] [Related]
3. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
4. DNA mismatch repair in cancer. Baretti M; Le DT Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy and patients treated for cancer with microsatellite instability. Colle R; Cohen R; Cochereau D; Duval A; Lascols O; Lopez-Trabada D; Afchain P; Trouilloud I; Parc Y; Lefevre JH; Fléjou JF; Svrcek M; André T Bull Cancer; 2017 Jan; 104(1):42-51. PubMed ID: 27979364 [TBL] [Abstract][Full Text] [Related]
6. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Kather JN; Halama N; Jaeger D Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787 [TBL] [Abstract][Full Text] [Related]
7. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Ballhausen A; Przybilla MJ; Jendrusch M; Haupt S; Pfaffendorf E; Seidler F; Witt J; Hernandez Sanchez A; Urban K; Draxlbauer M; Krausert S; Ahadova A; Kalteis MS; Pfuderer PL; Heid D; Stichel D; Gebert J; Bonsack M; Schott S; Bläker H; Seppälä T; Mecklin JP; Ten Broeke S; Nielsen M; Heuveline V; Krzykalla J; Benner A; Riemer AB; von Knebel Doeberitz M; Kloor M Nat Commun; 2020 Sep; 11(1):4740. PubMed ID: 32958755 [TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
9. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749 [TBL] [Abstract][Full Text] [Related]
10. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Chang L; Chang M; Chang HM; Chang F Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e15-e21. PubMed ID: 28877075 [TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. Kubecek O; Trojanova P; Molnarova V; Kopecky J Med Hypotheses; 2016 Aug; 93():74-6. PubMed ID: 27372860 [TBL] [Abstract][Full Text] [Related]
12. Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. Willis JA; Reyes-Uribe L; Chang K; Lipkin SM; Vilar E Clin Cancer Res; 2020 Jan; 26(1):11-17. PubMed ID: 31383734 [TBL] [Abstract][Full Text] [Related]
13. No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis. Stoehr R; Wendler O; Giedl J; Gaisa NT; Richter G; Campean V; Burger M; Wullich B; Bertz S; Hartmann A Pathobiology; 2019; 86(2-3):145-151. PubMed ID: 30650417 [TBL] [Abstract][Full Text] [Related]
14. Identifying Optimal Loci for the Molecular Diagnosis of Microsatellite Instability. Long DR; Waalkes A; Panicker VP; Hause RJ; Salipante SJ Clin Chem; 2020 Oct; 66(10):1310-1318. PubMed ID: 33001187 [TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers. Zhang P; Liu M; Cui Y; Zheng P; Liu Y Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32823273 [TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability status is determined by targeted sequencing with MSIcall in 25 cancer types. Hirotsu Y; Nagakubo Y; Amemiya K; Oyama T; Mochizuki H; Omata M Clin Chim Acta; 2020 Mar; 502():207-213. PubMed ID: 31730810 [TBL] [Abstract][Full Text] [Related]
17. The Immune Biology of Microsatellite-Unstable Cancer. Kloor M; von Knebel Doeberitz M Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532 [TBL] [Abstract][Full Text] [Related]
18. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747 [TBL] [Abstract][Full Text] [Related]
19. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. Viale G; Trapani D; Curigliano G Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222 [TBL] [Abstract][Full Text] [Related]